Cipla is looking at sustaining growth through the pandemic and has decided certain priorities for the coming quarters, including digital adoption and profitable growth. The drug firm has earmarked digital adoption and resilient operations as first of the key priorities for the coming quarters to achieve sustained growth.
The company is adopting digital transformation for patient and channel connect to expand access and leverage demand patterns, and is also proactively de-risking the business by diversifying sources for critical active pharmaceutical ingredients (APIs), intermediates and key starting materials (KSMs), and maintaining adequate inventory levels. The second priority for the coming quarters is on driving profitable growth. For this, the company is aiming at driving market-beating growth and scaling in India across its three businesses.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1801.20 |
| Dr. Reddys Lab | 1282.05 |
| Cipla | 1320.60 |
| Zydus Lifesciences | 904.70 |
| Lupin | 2339.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: